Aug. 10, 2010
Sinobiopharma, a biopharmaceutical products company with primary operations in China, has entered into a manufacturing, co-development and commercialization agreement with Jiangsu Lianhuan Pharmaceuticals (Lianhuan) for Eplerenone through its wholly-owned subsidiary Dong Ying (Jiangsu) Pharmaceutical.
Eplerenone is a therapeutic agent formulated to treat high blood pressure and vascular diseases.
Under the agreement, Sinobiopharma is expected to receive 60% of Eplerenone's profits.
In the framework of the co-development, Lianhuan shall finance and execute the clinical development, regulatory application and manufacturing of Eplerenone.